WEBULL
WebtradeDownload

Does J&J’s MONARCH QUEST 3 Approval and MedTech Momentum Change The Bull Case For Johnson & Johnson (JNJ)?

Simply Wall St · 1d ago
  • In recent days, Johnson & Johnson reported past quarterly operational sales growth led by its Innovative Medicine and MedTech businesses and raised its full-year outlook while securing U.S. 510(k) and FDA clearances for the MONARCH QUEST 3 AI-enabled bronchoscopy software update.
  • Taken together, stronger operating performance and regulatory progress in robotic lung procedures underscore how Johnson & Johnson is leaning on innovation across medicines and devices to reinforce its diversified healthcare model.
  • Next, we’ll examine how the MONARCH QUEST 3 approval and broader MedTech momentum may reshape Johnson & Johnson’s existing investment narrative.

AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Johnson & Johnson Investment Narrative Recap

To own Johnson & Johnson, you need to be comfortable with a diversified healthcare company that balances mature cash-generating products with heavy investment in new medicines and devices. The key near term catalyst is whether Innovative Medicine and MedTech can offset STELARA biosimilar pressure, while talc litigation and broader pricing/tariff risks remain significant overhangs. The MONARCH QUEST 3 clearance supports the MedTech story but does not materially change these top tier risks in the short term.

Within this context, the MONARCH QUEST 3 AI-enabled bronchoscopy clearance is especially relevant. It adds another proof point that MedTech is not just a stabilizer, but a source of potential growth as Johnson & Johnson advances robotic and minimally invasive procedures. For investors focused on whether MedTech can shoulder more of the load while key drugs face loss of exclusivity, this kind of regulatory progress is a practical, incremental positive.

Yet, beneath the innovation headlines, the ongoing talc litigation remains a risk investors should be aware of, because...

Read the full narrative on Johnson & Johnson (it's free!)

Johnson & Johnson's narrative projects $120.5 billion revenue and $28.6 billion earnings by 2029. This requires 7.2% yearly revenue growth and a $7.6 billion earnings increase from $21.0 billion.

Uncover how Johnson & Johnson's forecasts yield a $270.59 fair value, in line with its current price.

Exploring Other Perspectives

JNJ 1-Year Stock Price Chart
JNJ 1-Year Stock Price Chart

Some of the most optimistic analysts already expected Johnson & Johnson to reach about US$125.7 billion in revenue and US$29.6 billion in earnings by 2029, so you should recognize that views can differ widely and that fresh news like the MONARCH QUEST 3 approval or pricing pressure risks could easily shift those bullish expectations in ways worth comparing for yourself.

Explore 8 other fair value estimates on Johnson & Johnson - why the stock might be worth 14% less than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

Seeking Other Investments?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.